Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

TCT 2021 | Haploidentical vs matched donor transplantation in patients with myelofibrosis

Tania Jain • 12 Feb 2021
TCT 2021
Myelofibrosis Myeloproliferative Neoplasms

Tania Jain, MBBS, Johns Hopkins University, Baltimore, MD, provides an overview of the outcomes of haploidentical donor transplantation versus matched donor allogeneic hematopoietic cell transplantations in patients with myelofibrosis. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Tania Jain

Changes in the duration of the monitoring period following CAR T-cell infusion
1:35
Changes in the duration of the monitoring period following CAR T-cell infusion
Tania Jain • 23 Aug 2025
Strategies for mitigating infection risk in patients treated with CAR T-cell therapy
3:19
Strategies for mitigating infection risk in patients treated with CAR T-cell therapy
Tania Jain • 23 Aug 2025
Immunotherapy in MPNs: antibodies, CAR-T, and more
2:31
Immunotherapy in MPNs: antibodies, CAR-T, and more
Tania Jain • 23 Aug 2025
Cellular therapy modalities being explored for the prevention of post-transplant relapse
3:15
Cellular therapy modalities being explored for the prevention of post-transplant relapse
Tania Jain • 24 Aug 2024

Related Videos

Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Tania Jain • 6 Dec 2025
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
1:40
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
Tania Jain • 6 Dec 2025
The management of patients with ET or PV during pregnancy
3:32
The management of patients with ET or PV during pregnancy
Tania Jain • 7 Dec 2025
Preliminary analysis of the FEDORA trial: fedratinib plus ropeginterferon alfa-2b in myelofibrosis
2:37
Preliminary analysis of the FEDORA trial: fedratinib plus ropeginterferon alfa-2b in myelofibrosis
Tania Jain • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals